AR095562A1 - Cristales de laquinimod sódico y proceso mejorado para su fabricación - Google Patents
Cristales de laquinimod sódico y proceso mejorado para su fabricaciónInfo
- Publication number
- AR095562A1 AR095562A1 ARP140101184A ARP140101184A AR095562A1 AR 095562 A1 AR095562 A1 AR 095562A1 AR P140101184 A ARP140101184 A AR P140101184A AR P140101184 A ARP140101184 A AR P140101184A AR 095562 A1 AR095562 A1 AR 095562A1
- Authority
- AR
- Argentina
- Prior art keywords
- laquinimod
- amount
- methyl
- chloro
- hydroxy
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 17
- 229960004577 laquinimod Drugs 0.000 title abstract 17
- 238000000034 method Methods 0.000 title abstract 6
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 3
- 229910052708 sodium Inorganic materials 0.000 title abstract 3
- 239000011734 sodium Substances 0.000 title abstract 3
- 239000013078 crystal Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract 7
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 abstract 6
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 3
- 238000005259 measurement Methods 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- FTBWKSJUFWRKGL-UHFFFAOYSA-N 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound C1=CC(Cl)=C2C(O)=C(C(O)=O)C(=O)N(C)C2=C1 FTBWKSJUFWRKGL-UHFFFAOYSA-N 0.000 abstract 2
- ZFPGGAUWFSIDEL-UHFFFAOYSA-N 5-chloro-4-hydroxy-1-methylquinolin-2-one Chemical compound C1=CC(Cl)=C2C(O)=CC(=O)N(C)C2=C1 ZFPGGAUWFSIDEL-UHFFFAOYSA-N 0.000 abstract 2
- 229910001385 heavy metal Inorganic materials 0.000 abstract 2
- 239000012535 impurity Substances 0.000 abstract 2
- PAIDZDPOJWEZLX-UHFFFAOYSA-N methyl 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)OC)=C(O)C2=C1Cl PAIDZDPOJWEZLX-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- ZIPTZCNNYJFVOF-UHFFFAOYSA-N 2-chloro-6-[[3-(n-ethylanilino)-2-hydroxy-3-oxopropanoyl]-methylamino]benzoic acid Chemical compound C=1C=CC=CC=1N(CC)C(=O)C(O)C(=O)N(C)C1=CC=CC(Cl)=C1C(O)=O ZIPTZCNNYJFVOF-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- POQZLXDTXDVHMY-UHFFFAOYSA-N ethyl 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)OCC)=C(O)C2=C1Cl POQZLXDTXDVHMY-UHFFFAOYSA-N 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785575P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095562A1 true AR095562A1 (es) | 2015-10-28 |
Family
ID=50631081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101184A AR095562A1 (es) | 2013-03-14 | 2014-03-17 | Cristales de laquinimod sódico y proceso mejorado para su fabricación |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20160046582A1 (enExample) |
| EP (1) | EP2970129A2 (enExample) |
| JP (1) | JP2016514162A (enExample) |
| KR (1) | KR20150143499A (enExample) |
| CN (1) | CN105051013A (enExample) |
| AR (1) | AR095562A1 (enExample) |
| AU (1) | AU2014236232A1 (enExample) |
| BR (1) | BR112015021602A2 (enExample) |
| CA (1) | CA2901849A1 (enExample) |
| CL (1) | CL2015002712A1 (enExample) |
| EA (1) | EA201591699A1 (enExample) |
| HK (2) | HK1220444A1 (enExample) |
| IL (1) | IL240356A0 (enExample) |
| MX (1) | MX2015011627A (enExample) |
| NZ (1) | NZ630427A (enExample) |
| PE (1) | PE20151935A1 (enExample) |
| SG (1) | SG11201506409RA (enExample) |
| TW (1) | TW201519892A (enExample) |
| WO (1) | WO2014153145A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG183515A1 (en) * | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
| US9161935B2 (en) | 2012-02-03 | 2015-10-20 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| WO2014153145A2 (en) * | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| UY36099A (es) | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
| CN107966506B (zh) * | 2017-11-20 | 2019-09-13 | 福州大学 | 一种橡胶及橡胶制品中n-乙基苯胺含量的检测方法 |
| KR102069868B1 (ko) * | 2018-02-28 | 2020-01-23 | 고려대학교 산학협력단 | 합성가스 발효 균의 합성가스 발효 시의 대사체 분석을 위한 대사체 샘플링 및 분석 방법 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US607785A (en) | 1898-07-19 | Ore-car | ||
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
| TW376491B (en) | 1991-06-22 | 1999-12-11 | Fuji Xerox Co Ltd | Image processing system with a buffer memory |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| EP1022970B1 (en) | 1997-09-19 | 2003-11-26 | Cosco Management Inc. | Playyard |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| US6395750B1 (en) | 1999-10-25 | 2002-05-28 | Active Biotech Ab | Drugs for the treatment of malignant tumors |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| KR20140103356A (ko) | 2005-02-23 | 2014-08-26 | 테바 파마슈티컬 인더스트리즈 리미티드 | 함량 균일성이 개선된 라사길린 제형 |
| PL1902034T3 (pl) | 2005-06-02 | 2011-09-30 | Glenmark Pharmaceuticals Sa | Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania |
| CN107176923A (zh) * | 2005-10-19 | 2017-09-19 | 泰华制药工业有限公司 | 拉奎尼莫钠晶体及其制备方法 |
| KR20080112300A (ko) | 2006-03-16 | 2008-12-24 | 제넨테크, 인크. | Ｃｄ4 항체를 사용하여 루푸스를 치료하는 방법 |
| KR101495327B1 (ko) | 2006-06-12 | 2015-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| EP2056807B1 (en) | 2006-08-17 | 2012-09-26 | University Of Chicago | Treatment of inflammatory diseases |
| US20100260716A1 (en) | 2007-10-23 | 2010-10-14 | Ucb Pharma Gmbh | Compounds for treating demyelination conditions |
| US8178127B2 (en) | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
| WO2010001257A2 (en) | 2008-07-01 | 2010-01-07 | Actavis Group Ptc Ehf | Novel solid state forms of laquinimod and its sodium salt |
| CA2736091A1 (en) | 2008-09-03 | 2010-03-11 | Teva Pharmaceutical Industries Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| US20100260755A1 (en) | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| HUE026406T2 (en) | 2009-06-19 | 2016-06-28 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| CN105616410A (zh) | 2009-07-30 | 2016-06-01 | 泰华制药工业有限公司 | 利用拉喹莫德治疗克隆氏病 |
| ES2731052T3 (es) | 2009-08-10 | 2019-11-13 | Active Biotech Ab | Tratamiento de la enfermedad de Huntington usando laquinimod |
| KR20150135552A (ko) | 2010-03-03 | 2015-12-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| SG183515A1 (en) | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
| WO2011109531A1 (en) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| BR112013000607A2 (pt) | 2010-07-09 | 2016-06-28 | Teva Pharma | 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações |
| JP2013535437A (ja) | 2010-07-09 | 2013-09-12 | テバ ファーマシューティカル インダストリーズ リミティド | 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用 |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| JP2013544887A (ja) | 2010-12-07 | 2013-12-19 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用 |
| KR101130582B1 (ko) | 2011-06-07 | 2012-03-30 | 이대영 | 조립식 건축구조물의 골조연결장치 |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| CN103781355A (zh) | 2011-07-28 | 2014-05-07 | 泰华制药工业有限公司 | 用拉喹莫德与干扰素-β的组合治疗多发性硬化症 |
| US20130029916A1 (en) | 2011-07-28 | 2013-01-31 | Yossi Gilgun | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| US9161935B2 (en) | 2012-02-03 | 2015-10-20 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy |
| AR090073A1 (es) | 2012-02-16 | 2014-10-15 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| AR090885A1 (es) | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| WO2014004733A1 (en) | 2012-06-26 | 2014-01-03 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| UY34896A (es) | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| WO2014153145A2 (en) * | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
-
2014
- 2014-03-14 WO PCT/US2014/029292 patent/WO2014153145A2/en not_active Ceased
- 2014-03-14 NZ NZ630427A patent/NZ630427A/en not_active IP Right Cessation
- 2014-03-14 EA EA201591699A patent/EA201591699A1/ru unknown
- 2014-03-14 US US14/773,683 patent/US20160046582A1/en not_active Abandoned
- 2014-03-14 KR KR1020157029570A patent/KR20150143499A/ko not_active Withdrawn
- 2014-03-14 US US14/214,191 patent/US9233927B2/en not_active Expired - Fee Related
- 2014-03-14 CN CN201480014512.1A patent/CN105051013A/zh active Pending
- 2014-03-14 MX MX2015011627A patent/MX2015011627A/es unknown
- 2014-03-14 EP EP14721137.9A patent/EP2970129A2/en not_active Withdrawn
- 2014-03-14 AU AU2014236232A patent/AU2014236232A1/en not_active Abandoned
- 2014-03-14 BR BR112015021602A patent/BR112015021602A2/pt not_active IP Right Cessation
- 2014-03-14 PE PE2015001974A patent/PE20151935A1/es not_active Application Discontinuation
- 2014-03-14 JP JP2016503050A patent/JP2016514162A/ja not_active Withdrawn
- 2014-03-14 TW TW103109454A patent/TW201519892A/zh unknown
- 2014-03-14 HK HK16107245.0A patent/HK1220444A1/zh unknown
- 2014-03-14 CA CA2901849A patent/CA2901849A1/en not_active Abandoned
- 2014-03-14 HK HK16104113.6A patent/HK1216311A1/zh unknown
- 2014-03-14 SG SG11201506409RA patent/SG11201506409RA/en unknown
- 2014-03-17 AR ARP140101184A patent/AR095562A1/es unknown
-
2015
- 2015-08-04 IL IL240356A patent/IL240356A0/en unknown
- 2015-09-14 CL CL2015002712A patent/CL2015002712A1/es unknown
- 2015-12-03 US US14/958,396 patent/US20160158216A1/en not_active Abandoned
-
2017
- 2017-08-01 US US15/666,259 patent/US20170327464A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015002712A1 (es) | 2016-04-15 |
| IL240356A0 (en) | 2015-09-24 |
| US20160158216A1 (en) | 2016-06-09 |
| NZ630427A (en) | 2017-06-30 |
| WO2014153145A3 (en) | 2015-04-23 |
| US20160046582A1 (en) | 2016-02-18 |
| PE20151935A1 (es) | 2016-01-15 |
| US20140271878A1 (en) | 2014-09-18 |
| WO2014153145A2 (en) | 2014-09-25 |
| CN105051013A (zh) | 2015-11-11 |
| US9233927B2 (en) | 2016-01-12 |
| CA2901849A1 (en) | 2014-09-25 |
| US20170327464A1 (en) | 2017-11-16 |
| EA201591699A1 (ru) | 2016-02-29 |
| HK1216311A1 (zh) | 2016-11-04 |
| HK1220444A1 (zh) | 2017-05-05 |
| EP2970129A2 (en) | 2016-01-20 |
| AU2014236232A1 (en) | 2015-11-05 |
| JP2016514162A (ja) | 2016-05-19 |
| BR112015021602A2 (pt) | 2017-07-18 |
| MX2015011627A (es) | 2016-05-16 |
| KR20150143499A (ko) | 2015-12-23 |
| TW201519892A (zh) | 2015-06-01 |
| SG11201506409RA (en) | 2015-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095562A1 (es) | Cristales de laquinimod sódico y proceso mejorado para su fabricación | |
| Radhakrishnan et al. | Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly | |
| EP3793562B1 (en) | Methods and compositions for inhibition of dihydroorotate dehydrogenase | |
| PH12015500627A1 (en) | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives | |
| EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| EA201201343A1 (ru) | Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а | |
| MX355409B (es) | Proceso para la preparacion de n- [5- (3,5-difluoro-bencil) -1h-indazol-3-il] -4- (4-metil-piperazin-1-il) -2- (tetrahidro-piran-4-ilamino) -benzamida. | |
| SI3009431T1 (en) | 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer | |
| MX2015001370A (es) | N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a. | |
| WO2014105958A3 (en) | Fused pyrimidine compounds and use thereof | |
| MX2020002924A (es) | Lactamas fusionadas de arilo y heteroarilo. | |
| BR112015014222A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica | |
| PH12014502540A1 (en) | Benzimidazole-proline derivatives | |
| EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| ECSP14015609A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
| HK1197240A1 (en) | New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities | |
| IN2013MU03577A (enExample) | ||
| FR3002733B1 (fr) | Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| IN2014MN02380A (enExample) | ||
| CA2894715C (en) | Diazole amides | |
| WO2013006734A8 (en) | Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity | |
| AR090975A1 (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida | |
| WO2016130581A2 (en) | Combination cancer therapy | |
| MA35002B1 (fr) | Forme cristalline delta du sel d'arginine du périndopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| UA110822C2 (uk) | Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |